Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2016 (2016), Article ID 7190943, 16 pages
http://dx.doi.org/10.1155/2016/7190943
Review Article

Alternative Interventions to Prevent Oxidative Damage following Ischemia/Reperfusion

1Instituto de Terapéutica Experimental y Clínica, Departamento de Fisiología, CUCS, Universidad de Guadalajara, Calle Sierra Mojada 950, Colonia Independencia, 44340 Guadalajara, Jal, Mexico
2Laboratorio de Neurofisiología, Departamento de Fisiología, CUCS, Universidad de Guadalajara, Calle Sierra Mojada 950, Colonia Independencia, 44340 Guadalajara, Jal, Mexico

Received 21 June 2016; Revised 23 September 2016; Accepted 12 October 2016

Academic Editor: Kota V. Ramana

Copyright © 2016 Simón Quetzalcoatl Rodríguez-Lara et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. E. Murry, R. B. Jennings, and K. A. Reimer, “Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium,” Circulation, vol. 74, no. 5, pp. 1124–1136, 1986. View at Publisher · View at Google Scholar · View at Scopus
  2. R. B. Jennings, “Historical perspective on the pathology of myocardial ischemia/reperfusion injury,” Circulation Research, vol. 113, no. 4, pp. 428–438, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. A. T. Turer and J. A. Hill, “Pathogenesis of myocardial ischemia-reperfusion injury and rationale for therapy,” The American Journal of Cardiology, vol. 106, no. 3, pp. 360–368, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. V. L. Roger, A. S. Go, D. M. Lloyd-Jones et al., “Executive summary: heart disease and stroke statistics—2012 update: a report from the American Heart Association,” Circulation, vol. 125, no. 1, pp. 188–197, 2012. View at Google Scholar
  5. C. Cantú-Brito, J. L. Ruiz-Sandoval, L. M. Murillo-Bonilla et al., “Acute care and one-year outcome of Mexican patients with first-ever acute ischemic stroke: The PREMIER study,” Revista de Neurologia, vol. 51, no. 11, pp. 641–649, 2010. View at Google Scholar · View at Scopus
  6. R. G. Guzmán and J. A. Ramírez, Enfermedad Isquémica del Corazón, Epidemiología y Prevención, 2010.
  7. M. N. Á. Saldivar, A. E. O. Cruz, and H. J. R. Flores, “Enfermedad vascular cerebral: incidencia y factores de riesgo en el Hospital General La Perla,” Medicina Interna de México, vol. 28, no. 4, p. 342, 2012. View at Google Scholar
  8. R. Lozano, H. Gómez-Dantés, F. Garrido-Latorre et al., “La carga de enfermedad, lesiones, factores de riesgo y desafíos para el sistema de salud en México,” Salud Pública de México, vol. 55, no. 6, pp. 580–594, 2013. View at Google Scholar
  9. H. K. Eltzschig and T. Eckle, “Ischemia and reperfusion—from mechanism to translation,” Nature Medicine, vol. 17, no. 11, pp. 1391–1401, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. M. T. Dirksen, G. J. Laarman, M. L. Simoons, and D. J. G. M. Duncker, “Reperfusion injury in humans: a review of clinical trials on reperfusion injury inhibitory strategies,” Cardiovascular Research, vol. 74, no. 3, pp. 343–355, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. G. J. Gross and J. A. Auchampach, “Reperfusion injury: does it exist?” Journal of Molecular and Cellular Cardiology, vol. 42, no. 1, pp. 12–18, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. Z.-Q. Zhao and J. Vinten-Johansen, “Postconditioning: reduction of reperfusion-induced injury,” Cardiovascular Research, vol. 70, no. 2, pp. 200–211, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. Z.-Q. Zhao, J. S. Corvera, M. E. Halkos et al., “Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 285, no. 2, pp. H579–H588, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. L. Zhao, J. Y. Lee, and D. H. Hwang, “The phosphatidylinositol 3-kinase/Akt pathway negatively regulates Nod2-mediated NF-κB pathway,” Biochemical Pharmacology, vol. 75, no. 7, pp. 1515–1525, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. H. Zhao, “Ischemic postconditioning as a novel avenue to protect against brain injury after stroke,” Journal of Cerebral Blood Flow and Metabolism, vol. 29, no. 5, pp. 873–885, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Vinten-Johansen, Z.-Q. Zhao, R. Jiang, A. J. Zatta, and G. P. Dobson, “Preconditioning and postconditioning: innate cardioprotection from ischemia-reperfusion injury,” Journal of Applied Physiology, vol. 103, no. 4, pp. 1441–1448, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Kin, Z.-Q. Zhao, H.-Y. Sun et al., “Postconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting events in the early minutes of reperfusion,” Cardiovascular Research, vol. 62, no. 1, pp. 74–85, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. P. Staat, G. Rioufol, C. Piot et al., “Postconditioning the human heart,” Circulation, vol. 112, no. 14, pp. 2143–2148, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. Y. Tu, L. Wan, Y. Fan et al., “Ischemic postconditioning-mediated miRNA-21 protects against cardiac ischemia/reperfusion injury via PTEN/Akt pathway,” PLoS ONE, vol. 8, no. 10, Article ID e75872, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. C. Penna, D. Mancardi, S. Raimondo, S. Geuna, and P. Pagliaro, “The paradigm of postconditioning to protect the heart,” Journal of Cellular and Molecular Medicine, vol. 12, no. 2, pp. 435–458, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. T. Kalogeris, Y. Bao, and R. J. Korthuis, “Mitochondrial reactive oxygen species: a double edged sword in ischemia/reperfusion vs preconditioning,” Redox Biology, vol. 2, no. 1, pp. 702–714, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. T. Kalogeris, C. P. Baines, M. Krenz, and R. J. Korthuis, “Cell biology of ischemia/reperfusion injury,” International Review of Cell and Molecular Biology, vol. 298, pp. 229–317, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. C. H. Foyer and G. Noctor, “Redox sensing and signalling associated with reactive oxygen in chloroplasts, peroxisomes and mitochondria,” Physiologia Plantarum, vol. 119, no. 3, pp. 355–364, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. C. Lipina and H. S. Hundal, “Modulation of cellular redox homeostasis by the endocannabinoid system,” Open Biology, vol. 6, no. 4, Article ID 150276, 2016. View at Publisher · View at Google Scholar
  25. D. Trachootham, W. Lu, M. A. Ogasawara, N. R.-D. Valle, and P. Huang, “Redox regulation of cell survival,” Antioxidants and Redox Signaling, vol. 10, no. 8, pp. 1343–1374, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Barzegar and A. A. Moosavi-Movahedi, “Intracellular ROS protection efficiency and free radical-scavenging activity of curcumin,” PLoS ONE, vol. 6, no. 10, Article ID e26012, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. A. B. Kunnumakkara, P. Anand, and B. B. Aggarwal, “Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins,” Cancer Letters, vol. 269, no. 2, pp. 199–225, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. U. Singh, A. Barik, B. G. Singh, and K. I. Priyadarsini, “Reactions of reactive oxygen species (ROS) with curcumin analogues: structure-activity relationship,” Free Radical Research, vol. 45, no. 3, pp. 317–325, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. P. K. Sood, U. Nahar, and B. Nehru, “Curcumin attenuates aluminum-induced oxidative stress and mitochondrial dysfunction in rat brain,” Neurotoxicity Research, vol. 20, no. 4, pp. 351–361, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Li, Y.-M. Sun, L.-F. Wang, Z.-Q. Li, W. Pan, and H.-Y. Cao, “Comparison of effects of simvastatin versus atorvastatin on oxidative stress in patients with coronary heart disease,” Clinical Cardiology, vol. 33, no. 4, pp. 222–227, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Wang, J. Xu, C. Zhou et al., “Improvement of arterial stiffness by reducing oxidative stress damage in elderly hypertensive patients after 6 months of atorvastatin therapy,” Journal of Clinical Hypertension, vol. 14, no. 4, pp. 245–249, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. J. Yang, C. Liu, L. Zhang et al., “Intensive atorvastatin therapy attenuates the inflammatory responses in monocytes of patients with unstable angina undergoing percutaneous coronary intervention via peroxisome proliferator-activated receptor γ activation,” Inflammation, vol. 38, no. 4, pp. 1415–1423, 2015. View at Publisher · View at Google Scholar · View at Scopus
  33. P. Kovacic, R. Somanathan, and M. Abadjian, “Natural monophenols as therapeutics, antioxidants and toxins; electron transfer, radicals and oxidative stress,” The Natural Products Journal, vol. 5, no. 3, pp. 142–151, 2015. View at Publisher · View at Google Scholar
  34. R. S. Borges, J. Batista Jr., R. B. Viana et al., “Understanding the molecular aspects of tetrahydrocannabinol and cannabidiol as antioxidants,” Molecules, vol. 18, no. 10, pp. 12663–12674, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. P. Kovacic and R. Somanathan, “Cannabinoids (CBD, CBDHQ and THC): metabolism, physiological effects, electron transfer, reactive oxygen species and medical use,” The Natural Products Journal, vol. 4, no. 1, pp. 47–53, 2014. View at Publisher · View at Google Scholar
  36. R. Durst, H. Danenberg, R. Gallily et al., “Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 293, no. 6, pp. H3602–H3607, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Rajesh, P. Mukhopadhyay, S. Bátkai et al., “Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy,” Journal of the American College of Cardiology, vol. 56, no. 25, pp. 2115–2125, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. P. Mukhopadhyay, M. Rajesh, B. Horváth et al., “Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death,” Free Radical Biology and Medicine, vol. 50, no. 10, pp. 1368–1381, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. N. D. Volkow, R. D. Baler, W. M. Compton, and S. R. B. Weiss, “Adverse health effects of marijuana use,” The New England Journal of Medicine, vol. 370, no. 23, pp. 2219–2227, 2014. View at Publisher · View at Google Scholar · View at Scopus
  40. O. Devinsky, M. R. Cilio, H. Cross et al., “Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders,” Epilepsia, vol. 55, no. 6, pp. 791–802, 2014. View at Publisher · View at Google Scholar · View at Scopus
  41. C. Hindocha, T. P. Freeman, G. Schafer et al., “Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users,” European Neuropsychopharmacology, vol. 25, no. 3, pp. 325–334, 2015. View at Publisher · View at Google Scholar · View at Scopus
  42. J. M. McPartland, M. Duncan, V. Di Marzo, and R. G. Pertwee, “Are cannabidiol and Δ9-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review,” British Journal of Pharmacology, vol. 172, no. 3, pp. 737–753, 2015. View at Publisher · View at Google Scholar · View at Scopus
  43. A. W. Zuardi, J. A. S. Crippa, J. E. C. Hallak et al., “A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation,” Current Pharmaceutical Design, vol. 18, no. 32, pp. 5131–5140, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. H. R. Bridges, A. J. Y. Jones, M. N. Pollak, and J. Hirst, “Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria,” Biochemical Journal, vol. 462, no. 3, pp. 475–487, 2014. View at Publisher · View at Google Scholar · View at Scopus
  45. D. A. Kane, E. J. Anderson, J. W. Price et al., “Metformin selectively attenuates mitochondrial H2O2 emission without affecting respiratory capacity in skeletal muscle of obese rats,” Free Radical Biology and Medicine, vol. 49, no. 6, pp. 1082–1087, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. B. Viollet, B. Guigas, N. Sanz Garcia, J. Leclerc, M. Foretz, and F. Andreelli, “Cellular and molecular mechanisms of metformin: an overview,” Clinical Science, vol. 122, no. 6, pp. 253–270, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. W. W. Wheaton, S. E. Weinberg, R. B. Hamanaka et al., “Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis,” eLife, vol. 2014, no. 3, Article ID e02242, 2014. View at Publisher · View at Google Scholar · View at Scopus
  48. S. E. Inzucchi, K. J. Lipska, H. Mayo, C. J. Bailey, and D. K. McGuire, “Metformin in patients with type 2 diabetes and kidney disease: a systematic review,” The Journal of the American Medical Association, vol. 312, no. 24, pp. 2668–2675, 2014. View at Publisher · View at Google Scholar · View at Scopus
  49. M.-E. Lautatzis, D. G. Goulis, and M. Vrontakis, “Efficacy and safety of metformin during pregnancy in women with gestational diabetes mellitus or polycystic ovary syndrome: a systematic review,” Metabolism: Clinical and Experimental, vol. 62, no. 11, pp. 1522–1534, 2013. View at Publisher · View at Google Scholar · View at Scopus
  50. C. L. Morgan, J. Mukherjee, S. Jenkins-Jones, S. E. Holden, and C. J. Currie, “Combination therapy with metformin plus sulphonylureas versus metformin plus DPP-4 inhibitors: association with major adverse cardiovascular events and all-cause mortality,” Diabetes, Obesity and Metabolism, vol. 16, no. 10, pp. 977–983, 2014. View at Publisher · View at Google Scholar · View at Scopus
  51. A. Nakano, Y. Hattori, C. Aoki, T. Jojima, and K. Kasai, “Telmisartan inhibits cytokine-induced nuclear factor-κB activation independently of the peroxisome proliferator-activated receptorγ,” Hypertension Research, vol. 32, no. 9, pp. 765–769, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. G. Umpierrez, S. T. Povedano, F. P. Manghi, L. Shurzinske, and V. Pechtner, “Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3),” Diabetes Care, vol. 37, no. 8, pp. 2168–2176, 2014. View at Publisher · View at Google Scholar · View at Scopus
  53. K. Pilipović, Ž. Župan, P. Dolenec, J. Mršić-Pelčić, and G. Župan, “A single dose of PPARγ agonist pioglitazone reduces cortical oxidative damage and microglial reaction following lateral fluid percussion brain injury in rats,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 59, pp. 8–20, 2015. View at Publisher · View at Google Scholar · View at Scopus
  54. L. Sun, Q. Yuan, T. Xu et al., “Pioglitazone, a peroxisome proliferator-activated receptor γ agonist, ameliorates chronic kidney disease by enhancing antioxidative capacity and attenuating angiogenesis in the kidney of a 5/6 nephrectomized rat model,” Cellular Physiology and Biochemistry, vol. 38, no. 5, pp. 1831–1840, 2016. View at Publisher · View at Google Scholar
  55. C. Zou, H. Hu, X. Xi, Z. Shi, G. Wang, and X. Huang, “Pioglitazone protects against renal ischemia-reperfusion injury by enhancing antioxidant capacity,” Journal of Surgical Research, vol. 184, no. 2, pp. 1092–1095, 2013. View at Publisher · View at Google Scholar · View at Scopus
  56. I. Dovinová, M. Barancik, M. Majzunova et al., “Effects of PPARγ agonist pioglitazone on redox-sensitive cellular signaling in young spontaneously hypertensive rats,” PPAR Research, vol. 2013, Article ID 541871, 11 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  57. T. Hasegawa, K. Okada, Y. Okita, and D. J. Pinsky, “Antioxidant properties of pioglitazone limit nicotinamide adenine dinucleotide phosphate hydrogen oxidase and augment superoxide dismutase activity in cardiac allotransplantation,” Journal of Heart and Lung Transplantation, vol. 30, no. 10, pp. 1186–1196, 2011. View at Publisher · View at Google Scholar · View at Scopus
  58. T. Pang, J. Wang, J. Benicky, E. Sánchez-Lemus, and J. M. Saavedra, “Telmisartan directly ameliorates the neuronal inflammatory response to IL-1β partly through the JNK/c-Jun and NADPH oxidase pathways,” Journal of Neuroinflammation, vol. 9, article 102, 2012. View at Publisher · View at Google Scholar · View at Scopus
  59. B. DeJongh, K. Birkeland, and M. Brenner, “Managing comorbidities in patients with chronic heart failure: first, do no harm,” American Journal of Cardiovascular Drugs, vol. 15, no. 3, pp. 171–184, 2015. View at Publisher · View at Google Scholar · View at Scopus
  60. J. Hippisley-Cox and C. Coupland, “Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care,” British Medical Journal, vol. 354, Article ID i3477, 2016. View at Publisher · View at Google Scholar
  61. V. Jearath, R. Vashisht, V. Rustagi, S. Raina, and R. Sharma, “Pioglitazone-induced congestive heart failure and pulmonary edema in a patient with preserved ejection fraction,” Journal of Pharmacology and Pharmacotherapeutics, vol. 7, no. 1, p. 41, 2016. View at Publisher · View at Google Scholar
  62. J. J. V. McMurray, H. C. Gerstein, R. R. Holman, and M. A. Pfeffer, “Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored,” The Lancet Diabetes and Endocrinology, vol. 2, no. 10, pp. 843–851, 2014. View at Publisher · View at Google Scholar · View at Scopus
  63. S. Suh, G. H. Seo, C. H. Jung et al., “Increased risk of hospitalization for heart failure with newly prescribed dipeptidyl peptidase-4 inhibitors and pioglitazone using the Korean Health Insurance Claims Database,” Diabetes and Metabolism Journal, vol. 39, no. 3, pp. 247–252, 2015. View at Publisher · View at Google Scholar
  64. P. Ferdinandy, D. J. Hausenloy, G. Heusch, G. F. Baxter, and R. Schulz, “Interaction of risk factors, comorbidities, and comedications with ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning,” Pharmacological Reviews, vol. 66, no. 4, pp. 1142–1174, 2014. View at Publisher · View at Google Scholar · View at Scopus
  65. L. Cui, X. Zhang, R. Yang et al., “Neuroprotection of early and short-time applying atorvastatin in the acute phase of cerebral ischemia: down-regulated 12/15-LOX, p38MAPK and cPLA2 expression, ameliorated BBB permeability,” Brain Research, vol. 1325, pp. 164–173, 2010. View at Publisher · View at Google Scholar · View at Scopus
  66. E. Barone, G. Cenini, F. Di Domenico et al., “Long-term high-dose atorvastatin decreases brain oxidative and nitrosative stress in a preclinical model of Alzheimer disease: a novel mechanism of action,” Pharmacological Research, vol. 63, no. 3, pp. 172–180, 2011. View at Publisher · View at Google Scholar · View at Scopus
  67. A. C. Melo, S. S. Valença, L. B. Gitirana et al., “Redox markers and inflammation are differentially affected by atorvastatin, pravastatin or simvastatin administered before endotoxin-induced acute lung injury,” International Immunopharmacology, vol. 17, no. 1, pp. 57–64, 2013. View at Publisher · View at Google Scholar · View at Scopus
  68. E. Cadirci, A. Oral, F. Odabasoglu et al., “Atorvastatin reduces tissue damage in rat ovaries subjected to torsion and detorsion: biochemical and histopathologic evaluation,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 381, no. 5, pp. 455–466, 2010. View at Publisher · View at Google Scholar · View at Scopus
  69. K. Axsom, J. S. Berger, and A. Z. Schwartzbard, “Statins and diabetes: the good, the bad, and the unknown,” Current atherosclerosis reports, vol. 15, no. 2 , article 299, 2013. View at Publisher · View at Google Scholar · View at Scopus
  70. G. Danaei, L. A. García Rodríguez, O. F. Cantero, and M. A. Hernán, “Statins and risk of diabetes: an analysis of electronic medical records to evaluate possible bias due to differential survival,” Diabetes Care, vol. 36, no. 5, pp. 1236–1240, 2013. View at Publisher · View at Google Scholar · View at Scopus
  71. M. R. Goldstein and L. Mascitelli, “Do statins cause diabetes?” Current Diabetes Reports, vol. 13, no. 3, pp. 381–390, 2013. View at Publisher · View at Google Scholar · View at Scopus
  72. M. B. Rocco, “Statins and diabetes risk: fact, fiction, and clinical implications,” Cleveland Clinic Journal of Medicine, vol. 79, no. 12, pp. 883–893, 2012. View at Publisher · View at Google Scholar · View at Scopus
  73. D. I. Swerdlow and N. Sattar, “A dysglycaemic effect of statins in diabetes: relevance to clinical practice?” Diabetologia, vol. 57, no. 12, pp. 2433–2435, 2014. View at Publisher · View at Google Scholar · View at Scopus
  74. Q. Zhou and J. K. Liao, “Pleiotropic effects of statins: basic research and clinical perspectives,” Circulation Journal, vol. 74, no. 5, pp. 818–826, 2010. View at Publisher · View at Google Scholar · View at Scopus
  75. Y. Kumtepe, F. Odabasoglu, M. Karaca et al., “Protective effects of telmisartan on ischemia/reperfusion injury of rat ovary: biochemical and histopathologic evaluation,” Fertility and Sterility, vol. 93, no. 4, pp. 1299–1307, 2010. View at Publisher · View at Google Scholar · View at Scopus
  76. I.-N. Bähr, P. Tretter, J. Krüger et al., “High-dose treatment with telmisartan induces monocytic peroxisome proliferator-activated receptor-γ target genes in patients with the metabolic syndrome,” Hypertension, vol. 58, no. 4, pp. 725–732, 2011. View at Publisher · View at Google Scholar · View at Scopus
  77. H. Fujita, H. Fujishima, T. Morii et al., “Modulation of renal superoxide dismutase by telmisartan therapy in C57BL/6-Ins2(Akita) diabetic mice,” Hypertension Research, vol. 35, no. 2, pp. 213–220, 2012. View at Publisher · View at Google Scholar
  78. H. He, D. Yang, L. Ma et al., “Telmisartan prevents weight gain and obesity through activation of peroxisome proliferator-activated receptor-δ-dependent pathways,” Hypertension, vol. 55, no. 4, pp. 869–879, 2010. View at Publisher · View at Google Scholar · View at Scopus
  79. A. S. Kumar, S. Ghosh, and G. N. Mehta, “Efficient and improved synthesis of Telmisartan,” Beilstein Journal of Organic Chemistry, vol. 6, article 25, 2010. View at Publisher · View at Google Scholar · View at Scopus
  80. K. Washida, M. Ihara, K. Nishio et al., “Nonhypotensive dose of telmisartan attenuates cognitive impairment partially due to peroxisome proliferator-activated receptor-γ activation in mice with chronic cerebral hypoperfusion,” Stroke, vol. 41, no. 8, pp. 1798–1806, 2010. View at Publisher · View at Google Scholar · View at Scopus
  81. M. Dessì, A. Piras, C. Madeddu et al., “Long-term protective effects of the angiotensin receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress and myocardial dysfunction,” Experimental and Therapeutic Medicine, vol. 2, no. 5, pp. 1003–1009, 2011. View at Publisher · View at Google Scholar · View at Scopus
  82. X. Feng, Z. Luo, L. Ma et al., “Angiotensin II receptor blocker telmisartan enhances running endurance of skeletal muscle through activation of the PPAR-δ/AMPK pathway,” Journal of Cellular and Molecular Medicine, vol. 15, no. 7, pp. 1572–1581, 2011. View at Publisher · View at Google Scholar · View at Scopus
  83. H. Fujita, T. Sakamoto, K. Komatsu et al., “Reduction of circulating superoxide dismutase activity in type 2 diabetic patients with microalbuminuria and its modulation by telmisartan therapy,” Hypertension Research, vol. 34, no. 12, pp. 1302–1308, 2011. View at Publisher · View at Google Scholar · View at Scopus
  84. M. Knorr, M. Hausding, S. Kröller-Schuhmacher et al., “Nitroglycerin-induced endothelial dysfunction and tolerance involve adverse phosphorylation and S-glutathionylation of endothelial nitric oxide synthase: beneficial effects of therapy with the AT1 receptor blocker telmisartan,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 31, no. 10, pp. 2223–2231, 2011. View at Publisher · View at Google Scholar · View at Scopus
  85. Y. Maejima, H. Okada, G. Haraguchi et al., “Telmisartan, a unique ARB, improves left ventricular remodeling of infarcted heart by activating PPAR gamma,” Laboratory Investigation, vol. 91, no. 6, pp. 932–944, 2011. View at Publisher · View at Google Scholar · View at Scopus
  86. C. Yumin, L. Qiong, X. Zibo, L. Wei, C. Li, and X. Zuying, “Telmisartan counteracts TGF-β1 induced epithelial-to-mesenchymal transition via PPAR-γ in human proximal tubule epithelial cells,” International Journal of Clinical and Experimental Pathology, vol. 5, no. 6, pp. 522–529, 2012. View at Google Scholar · View at Scopus
  87. H. Kusunoki, Y. Taniyama, J. Azuma et al., “Telmisartan exerts renoprotective actions via peroxisome proliferator-activated receptor-γ/hepatocyte growth factor pathway independent of angiotensin II type 1 receptor blockade,” Hypertension, vol. 59, no. 2, pp. 308–316, 2012. View at Publisher · View at Google Scholar · View at Scopus
  88. T. Pang, J. Benicky, J. Wang, M. Orecna, E. Sanchez-Lemus, and J. M. Saavedra, “Telmisartan ameliorates lipopolysaccharide-induced innate immune response through peroxisome proliferator-activated receptor-γ activation in human monocytes,” Journal of Hypertension, vol. 30, no. 1, pp. 87–96, 2012. View at Publisher · View at Google Scholar · View at Scopus
  89. K. Ozeki, S. Tanida, C. Morimoto et al., “Telmisartan inhibits cell proliferation by blocking nuclear translocation of ProHB-EGF C-terminal fragment in colon cancer cells,” PLoS ONE, vol. 8, no. 2, Article ID e56770, 2013. View at Publisher · View at Google Scholar · View at Scopus
  90. K. Takeuchi, K. Yamamoto, M. Ohishi et al., “Telmisartan modulates mitochondrial function in vascular smooth muscle cells,” Hypertension Research, vol. 36, no. 5, pp. 433–439, 2013. View at Publisher · View at Google Scholar · View at Scopus
  91. R. L. Engler, G. W. SchmidSchonbein, and R. S. Pavelec, “Leukocyte capillary plugging in myocardial ischemia and reperfusion in the dog,” American Journal of Pathology, vol. 111, no. 1, pp. 98–111, 1983. View at Google Scholar · View at Scopus
  92. D. J. Hausenloy and D. M. Yellon, “Myocardial ischemia-reperfusion injury: a neglected therapeutic target,” The Journal of Clinical Investigation, vol. 123, no. 1, pp. 92–100, 2013. View at Publisher · View at Google Scholar · View at Scopus
  93. J. Huffmyer and J. Raphael, “Physiology and pharmacology of myocardial preconditioning and postconditioning,” Seminars in Cardiothoracic and Vascular Anesthesia, vol. 13, no. 1, pp. 5–18, 2009. View at Publisher · View at Google Scholar · View at Scopus
  94. D. Hilfiker-Kleiner, K. Kaminski, A. Kaminska et al., “Regulation of proangiogenic factor CCN1 in cardiac muscle: impact of ischemia, pressure overload, and neurohumoral activation,” Circulation, vol. 109, no. 18, pp. 2227–2233, 2004. View at Publisher · View at Google Scholar · View at Scopus
  95. J. Li, H. Zhang, and C. Zhang, “Role of inflammation in the regulation of coronary blood flow in ischemia and reperfusion: mechanisms and therapeutic implications,” Journal of Molecular and Cellular Cardiology, vol. 52, no. 4, pp. 865–872, 2012. View at Publisher · View at Google Scholar · View at Scopus
  96. Y. Zhai, H. Petrowsky, J. C. Hong, R. W. Busuttil, and J. W. Kupiec-Weglinski, “Ischaemia-reperfusion injury in liver transplantation-from bench to bedside,” Nature Reviews Gastroenterology and Hepatology, vol. 10, no. 2, pp. 79–89, 2013. View at Publisher · View at Google Scholar · View at Scopus
  97. Y. Zhai, R. W. Busuttil, and J. W. Kupiec-Weglinski, “Liver ischemia and reperfusion injury: new insights into mechanisms of innate-adaptive immune-mediated tissue inflammation,” American Journal of Transplantation, vol. 11, no. 8, pp. 1563–1569, 2011. View at Publisher · View at Google Scholar · View at Scopus
  98. J. G. Godwin, X. Ge, K. Stephan, A. Jurisch, S. G. Tullius, and J. Iacomini, “Identification of a microRNA signature of renal ischemia reperfusion injury,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 32, pp. 14339–14344, 2010. View at Publisher · View at Google Scholar · View at Scopus
  99. E. K. van den Akker, O. C. Manintveld, D. A. Hesselink, R. W. F. de Bruin, J. N. M. Ijzermans, and F. J. M. F. Dor, “Protection against renal ischemia-reperfusion injury by ischemic postconditioning,” Transplantation, vol. 95, no. 11, pp. 1299–1305, 2013. View at Publisher · View at Google Scholar · View at Scopus
  100. A. Kezic, I. Spasojevic, V. Lezaic, and M. Bajcetic, “Mitochondria-targeted antioxidants: future perspectives in kidney ischemia reperfusion injury,” Oxidative Medicine and Cellular Longevity, vol. 2016, Article ID 2950503, 12 pages, 2016. View at Publisher · View at Google Scholar
  101. S. Paradis, A. Charles, A. Meyer et al., “Chronology of mitochondrial and cellular events during skeletal muscle ischemia-reperfusion,” American Journal of Physiology—Cell Physiology, vol. 310, no. 11, pp. C968–C982, 2016. View at Publisher · View at Google Scholar
  102. C. A. da Silva Frias Neto, M. K. Koike, K. R. Saad, P. F. Saad, and E. F. de Souza Montero, “Effects of ischemic preconditioning and cilostazol on muscle ischemia-reperfusion injury in rats,” Acta Cirurgica Brasileira, vol. 29, pp. 17–21, 2014. View at Publisher · View at Google Scholar · View at Scopus
  103. E. M. Carmo-Araújo, M. Dal-Pai-Silva, V. Dal-Pai, R. Cecchini, and A. L. Anjos Ferreira, “Ischaemia and reperfusion effects on skeletal muscle tissue: morphological and histochemical studies,” International Journal of Experimental Pathology, vol. 88, no. 3, pp. 147–154, 2007. View at Publisher · View at Google Scholar · View at Scopus
  104. K. Koca, Y. Yurttas, S. Bilgic et al., “Effect of preconditioned hyperbaric oxygen and ozone on ischemia-reperfusion induced tourniquet in skeletal bone of rats,” Journal of Surgical Research, vol. 164, no. 1, pp. e83–e89, 2010. View at Publisher · View at Google Scholar · View at Scopus
  105. D. B. Rylatt, A. Aitken, T. Bilham, G. D. Condon, N. Embi, and P. Cohen, “Glycogen synthase from rabbit skeletal muscle. Amino acid sequence at the sites phosphorylated by glycogen synthase kinase-3, and extension of the N-terminal sequence containing the site phosphorylated by phosphorylase kinase,” European Journal of Biochemistry, vol. 107, no. 2, pp. 529–537, 1980. View at Google Scholar · View at Scopus
  106. T. P. Tran, H. Tu, I. I. Pipinos, R. L. Muelleman, H. Albadawi, and Y.-L. Li, “Tourniquet-induced acute ischemia-reperfusion injury in mouse skeletal muscles: involvement of superoxide,” European Journal of Pharmacology, vol. 650, no. 1, pp. 328–334, 2011. View at Publisher · View at Google Scholar · View at Scopus
  107. A. Y. Andreyev, Y. E. Kushnareva, and A. A. Starkov, “Mitochondrial metabolism of reactive oxygen species,” Biochemistry, vol. 70, no. 2, pp. 200–214, 2005. View at Publisher · View at Google Scholar · View at Scopus
  108. O. Gateau-Roesch, L. Argaud, and M. Ovize, “Mitochondrial permeability transition pore and postconditioning,” Cardiovascular Research, vol. 70, no. 2, pp. 264–273, 2006. View at Publisher · View at Google Scholar · View at Scopus
  109. L. Argaud, O. Gateau-Roesch, O. Raisky, J. Loufouat, D. Robert, and M. Ovize, “Postconditioning inhibits mitochondrial permeability transition,” Circulation, vol. 111, no. 2, pp. 194–197, 2005. View at Publisher · View at Google Scholar · View at Scopus
  110. G. Benard, B. Faustin, E. Passerieux et al., “Physiological diversity of mitochondrial oxidative phosphorylation,” American Journal of Physiology—Cell Physiology, vol. 291, no. 6, pp. C1172–C1182, 2006. View at Publisher · View at Google Scholar · View at Scopus
  111. M. D. Brand and D. G. Nicholls, “Assessing mitochondrial dysfunction in cells,” Biochemical Journal, vol. 435, no. 2, pp. 297–312, 2011. View at Publisher · View at Google Scholar · View at Scopus
  112. P. Ghafourifar and E. Cadenas, “Mitochondrial nitric oxide synthase,” Trends in Pharmacological Sciences, vol. 26, no. 4, pp. 190–195, 2005. View at Publisher · View at Google Scholar · View at Scopus
  113. G. Heusch, J. Musiolik, N. Gedik, and A. Skyschally, “Mitochondrial STAT3 activation and cardioprotection by ischemic postconditioning in pigs with regional myocardial ischemia/reperfusion,” Circulation Research, vol. 109, no. 11, pp. 1302–1308, 2011. View at Publisher · View at Google Scholar · View at Scopus
  114. D. Obal, S. Dettwiler, C. Favoccia, H. Scharbatke, B. Preckel, and W. Schlack, “The influence of mitochondrial KATP-channels in the cardioprotection of preconditioning and postconditioning by sevoflurane in the rat in vivo,” Anesthesia and Analgesia, vol. 101, no. 5, pp. 1252–1260, 2005. View at Publisher · View at Google Scholar · View at Scopus
  115. J. M. Suski, M. Lebiedzinska, M. Bonora, P. Pinton, J. Duszynski, and M. R. Wieckowski, “Relation between mitochondrial membrane potential and ROS formation,” Methods in Molecular Biology, vol. 810, pp. 183–205, 2012. View at Publisher · View at Google Scholar · View at Scopus
  116. A. G. Estévez and J. Jordán, “Nitric oxide and superoxide, a deadly cocktail,” Annals of the New York Academy of Sciences, vol. 962, pp. 207–211, 2002. View at Publisher · View at Google Scholar · View at Scopus
  117. M. W. Broadhead, R. K. Kharbanda, M. J. Peters, and R. J. MacAllister, “KATP channel activation induces ischemic preconditioning of the endothelium in humans in vivo,” Circulation, vol. 110, no. 15, pp. 2077–2082, 2004. View at Publisher · View at Google Scholar · View at Scopus
  118. S. P. Loukogeorgakis, R. Williams, A. T. Panagiotidou et al., “Transient limb ischemia induces remote preconditioning and remote postconditioning in humans by a KATP channel–dependent mechanism,” Circulation, vol. 116, no. 12, pp. 1386–1395, 2007. View at Publisher · View at Google Scholar · View at Scopus
  119. E. Birben, U. M. Sahiner, C. Sackesen, S. Erzurum, and O. Kalayci, “Oxidative stress and antioxidant defense,” World Allergy Organization Journal, vol. 5, no. 1, pp. 9–19, 2012. View at Publisher · View at Google Scholar · View at Scopus
  120. A. Daiber, M. Mader, P. Stamm et al., “Oxidative stress and vascular function,” Cell Membranes and Free Radical Research, vol. 5, no. 1, pp. 221–232, 2013. View at Google Scholar · View at Scopus
  121. K. Jomova, D. Vondrakova, M. Lawson, and M. Valko, “Metals, oxidative stress and neurodegenerative disorders,” Molecular and Cellular Biochemistry, vol. 345, no. 1-2, pp. 91–104, 2010. View at Publisher · View at Google Scholar · View at Scopus
  122. D. P. Jones, “Redefining oxidative stress,” Antioxidants & Redox Signaling, vol. 8, no. 9-10, pp. 1865–1879, 2006. View at Publisher · View at Google Scholar · View at Scopus
  123. M. P. Lesser, “Oxidative stress in marine environments: biochemistry and physiological ecology,” Annual Review of Physiology, vol. 68, pp. 253–278, 2006. View at Publisher · View at Google Scholar · View at Scopus
  124. J. Li, O. Wuliji, W. Li, Z.-G. Jiang, and H. A. Ghanbari, “Oxidative stress and neurodegenerative disorders,” International Journal of Molecular Sciences, vol. 14, no. 12, pp. 24438–24475, 2013. View at Publisher · View at Google Scholar · View at Scopus
  125. G.-Y. Liou and P. Storz, “Reactive oxygen species in cancer,” Free Radical Research, vol. 44, no. 5, pp. 479–496, 2010. View at Publisher · View at Google Scholar · View at Scopus
  126. M. J. Morgan and Z.-G. Liu, “Crosstalk of reactive oxygen species and NF-κB signaling,” Cell Research, vol. 21, no. 1, pp. 103–115, 2011. View at Publisher · View at Google Scholar · View at Scopus
  127. S. M. Davidson and M. R. Duchen, “Endothelial mitochondria: contributing to vascular function and disease,” Circulation Research, vol. 100, no. 8, pp. 1128–1141, 2007. View at Publisher · View at Google Scholar · View at Scopus
  128. J. P. Kehrer, “The Haber-Weiss reaction and mechanisms of toxicity,” Toxicology, vol. 149, no. 1, pp. 43–50, 2000. View at Publisher · View at Google Scholar · View at Scopus
  129. Y. Takada, A. Mukhopadhyay, G. C. Kundu, G. H. Mahabeleshwar, S. Singh, and B. B. Aggarwal, “Hydrogen peroxide activates NF-κB through tyrosine phosphorylation of IκBα and serine phosphorylation of p65. Evidence for the involvement of IκBα kinase and Syk protein-tyrosine kinase,” The Journal of Biological Chemistry, vol. 278, no. 26, pp. 24233–24241, 2003. View at Publisher · View at Google Scholar · View at Scopus
  130. B. Kalyanaraman, “Teaching the basics of redox biology to medical and graduate students: oxidants, antioxidants and disease mechanisms,” Redox Biology, vol. 1, no. 1, pp. 244–257, 2013. View at Publisher · View at Google Scholar · View at Scopus
  131. J. Camps, A. García-Heredia, A. Rull et al., “PPARs in regulation of paraoxonases: control of oxidative stress and inflammation pathways,” PPAR Research, vol. 2012, Article ID 616371, 10 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  132. J. Ninomiya-Tsuji, K. Kishimoto, A. Hiyama, J.-I. Inoue, Z. Cao, and K. Matsumoto, “The kinase TAK1 can activate the NIK-IκB as well as the MAP kinase cascade in the IL-1 signalling pathway,” Nature, vol. 398, no. 6724, pp. 252–256, 1999. View at Publisher · View at Google Scholar · View at Scopus
  133. K. Schulze-Osthoff, D. Ferrari, K. Riehemann, and S. Wesselborg, “Regulation of NF-κB activation by MAP kinase cascades,” Immunobiology, vol. 198, no. 1-3, pp. 35–49, 1997. View at Publisher · View at Google Scholar · View at Scopus
  134. N. L. Malinin, M. P. Boldin, A. V. Kovalenko, and D. Wallach, “MAP3K-related kinase involved in NF-κB induction by TNF, CD95 and IL-1,” Nature, vol. 385, no. 6616, pp. 540–544, 1997. View at Publisher · View at Google Scholar · View at Scopus
  135. P. Tieri, A. Termanini, E. Bellavista, S. Salvioli, M. Capri, and C. Franceschi, “Charting the NF-κB pathway interactome map,” PLoS ONE, vol. 7, no. 3, Article ID e32678, 2012. View at Publisher · View at Google Scholar · View at Scopus
  136. T. Bouwmeester, A. Bauch, H. Ruffner et al., “A physical and functional map of the human TNF-α/NF-κB signal transduction pathway,” Nature Cell Biology, vol. 6, no. 2, pp. 97–105, 2004. View at Publisher · View at Google Scholar · View at Scopus
  137. E. De Smaele, F. Zazzeroni, S. Papa et al., “Induction of gadd4β by NF-κB downregulates pro-apoptotic JNK signalling,” Nature, vol. 414, no. 6861, pp. 308–313, 2001. View at Publisher · View at Google Scholar · View at Scopus
  138. S. Papa, F. Zazzeroni, C. Bubici et al., “Gadd45β mediates the NF-κB suppression of JNK signalling by targeting MKK7/JNKK2,” Nature Cell Biology, vol. 6, no. 2, pp. 146–153, 2004. View at Publisher · View at Google Scholar · View at Scopus
  139. N. D. Perkins, “Integrating cell-signalling pathways with NF-κB and IKK function,” Nature Reviews Molecular Cell Biology, vol. 8, no. 1, pp. 49–62, 2007. View at Publisher · View at Google Scholar
  140. M. Zhu, J. Feng, E. Lucchinetti et al., “Ischemic postconditioning protects remodeled myocardium via the PI3K-PKB/Akt reperfusion injury salvage kinase pathway,” Cardiovascular Research, vol. 72, no. 1, pp. 152–162, 2006. View at Publisher · View at Google Scholar · View at Scopus
  141. M. Guha and N. Mackman, “The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells,” Journal of Biological Chemistry, vol. 277, no. 35, pp. 32124–32132, 2002. View at Publisher · View at Google Scholar · View at Scopus
  142. D. J. Hausenloy and D. M. Yellon, “Survival kinases in ischemic preconditioning and postconditioning,” Cardiovascular Research, vol. 70, no. 2, pp. 240–253, 2006. View at Publisher · View at Google Scholar · View at Scopus
  143. A. A. Habib, S. Chatterjee, S.-K. Park, R. R. Ratan, S. Lefebvre, and T. Vartanian, “The epidermal growth factor receptor engages receptor interacting protein and nuclear factor-κB (NF-κB)-inducing kinase to activate NF-κB: identification of a novel receptor-tyrosine kinase signalosome,” The Journal of Biological Chemistry, vol. 276, no. 12, pp. 8865–8874, 2001. View at Publisher · View at Google Scholar · View at Scopus
  144. Y. C. Park, C. H. Lee, H. S. Kang, H. T. Chung, and H. D. Kim, “Wortmannin, a specific inhibitor of phosphatidylinositol-3-kinase, enhances LPS-induced NO production from murine peritoneal macrophages,” Biochemical and Biophysical Research Communications, vol. 240, no. 3, pp. 692–696, 1997. View at Publisher · View at Google Scholar · View at Scopus
  145. D. Wang, S. D. Westerheide, J. L. Hanson, and A. S. Baldwin Jr., “Tumor necrosis factor α-induced phosphorylation of RelA/p65 on Ser529 is controlled by casein kinase II,” The Journal of Biological Chemistry, vol. 275, no. 42, pp. 32592–32597, 2000. View at Publisher · View at Google Scholar · View at Scopus
  146. Q. Zhao and F. S. Lee, “Mitogen-activated protein kinase/ERK kinase kinases 2 and 3 activate nuclear factor-κB through IκB kinase-α and IκB kinase-β,” Journal of Biological Chemistry, vol. 274, no. 13, pp. 8355–8358, 1999. View at Publisher · View at Google Scholar · View at Scopus
  147. M. Delhase, S.-Y. Kim, H. Lee et al., “Correction for Delhase et al., TANK-binding kinase 1 (TBK1) controls cell survival through PAI-2/serpinB2 and transglutaminase 2,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 11, pp. 4332–4335, 2012. View at Publisher · View at Google Scholar · View at Scopus
  148. C. Alberti, P. Pinciroli, B. Valeri et al., “Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer,” Oncogene, vol. 31, no. 37, pp. 4139–4149, 2012. View at Publisher · View at Google Scholar · View at Scopus
  149. D. P. Bartel, “MicroRNAs: genomics, biogenesis, mechanism, and function,” Cell, vol. 116, no. 2, pp. 281–297, 2004. View at Publisher · View at Google Scholar · View at Scopus
  150. D. P. Bartel, “MicroRNAs: target Recognition and Regulatory Functions,” Cell, vol. 136, no. 2, pp. 215–233, 2009. View at Publisher · View at Google Scholar · View at Scopus
  151. J. Bauersachs and T. Thum, “Biogenesis and regulation of cardiovascular MicroRNAs,” Circulation Research, vol. 109, no. 3, pp. 334–347, 2011. View at Publisher · View at Google Scholar · View at Scopus
  152. A. K. Frank, J. I.-J. Leu, Y. Zhou et al., “The codon 72 polymorphism of p53 regulates interaction with NF-κB and transactivation of genes involved in immunity and inflammation,” Molecular and Cellular Biology, vol. 31, no. 6, pp. 1201–1213, 2011. View at Publisher · View at Google Scholar · View at Scopus
  153. D. Iliopoulos, H. A. Hirsch, and K. Struhl, “An epigenetic switch involving NF-κB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation,” Cell, vol. 139, no. 4, pp. 693–706, 2009. View at Publisher · View at Google Scholar · View at Scopus
  154. A. Oeckinghaus and S. Ghosh, “The NF-kappaB family of transcription factors and its regulation,” Cold Spring Harbor Perspectives in Biology, vol. 1, no. 4, Article ID a000034, 2009. View at Publisher · View at Google Scholar
  155. H. Sabatel, E. Di Valentin, G. Gloire, F. Dequiedt, J. Piette, and Y. Habraken, “Phosphorylation of p65(ReLA) on ser 547 by ATM represses NF-κb-dependent transcription of specific genes after genotoxic stress,” PLoS ONE, vol. 7, no. 6, Article ID e38246, 2012. View at Publisher · View at Google Scholar · View at Scopus
  156. T.-X. Xie, Z. Xia, N. Zhang, W. Gong, and S. Huang, “Constitutive NF-κB activity regulates the expression of VEGF and IL-8 and tumor angiogenesis of human glioblastoma,” Oncology Reports, vol. 23, no. 3, pp. 725–732, 2010. View at Publisher · View at Google Scholar · View at Scopus
  157. Z. Pan, X. Sun, J. Ren et al., “miR-1 Exacerbates Cardiac Ischemia-Reperfusion Injury in Mouse Models,” PLoS ONE, vol. 7, no. 11, Article ID e50515, 2012. View at Publisher · View at Google Scholar · View at Scopus
  158. R. W. Carthew and E. J. Sontheimer, “Origins and mechanisms of miRNAs and siRNAs,” Cell, vol. 136, no. 4, pp. 642–655, 2009. View at Publisher · View at Google Scholar · View at Scopus
  159. T. Li, M. J. Morgan, S. Choksi, Y. Zhang, Y.-S. Kim, and Z.-G. Liu, “MicroRNAs modulate the noncanonical transcription factor NF-κB pathway by regulating expression of the kinase IKKα during macrophage differentiation,” Nature Immunology, vol. 11, no. 9, pp. 799–805, 2010. View at Publisher · View at Google Scholar · View at Scopus
  160. X. Ma, L. E. Becker Buscaglia, J. R. Barker, and Y. Li, “MicroRNAs in NF-κB signaling,” Journal of Molecular Cell Biology, vol. 3, no. 3, pp. 159–166, 2011. View at Publisher · View at Google Scholar · View at Scopus
  161. J. Niu, Y. Shi, G. Tan et al., “DNA damage induces NF-κB-dependent microRNA-21 up-regulation and promotes breast cancer cell invasion,” The Journal of Biological Chemistry, vol. 287, no. 26, pp. 21783–21795, 2012. View at Publisher · View at Google Scholar · View at Scopus
  162. B. Schroen and S. Heymans, “Small but smart—microRNAs in the centre of inflammatory processes during cardiovascular diseases, the metabolic syndrome, and ageing,” Cardiovascular Research, vol. 93, no. 4, pp. 605–613, 2012. View at Publisher · View at Google Scholar · View at Scopus
  163. Y. Ye, J. R. Perez-Polo, J. Qian, and Y. Birnbaum, “The role of microRNA in modulating myocardial ischemia-reperfusion injury,” Physiological Genomics, vol. 43, no. 10, pp. 534–542, 2011. View at Publisher · View at Google Scholar · View at Scopus
  164. S. Zhang, C. Shan, G. Kong, Y. Du, L. Ye, and X. Zhang, “MicroRNA-520e suppresses growth of hepatoma cells by targeting the NF-κB-inducing kinase (NIK),” Oncogene, vol. 31, no. 31, pp. 3607–3620, 2012. View at Publisher · View at Google Scholar · View at Scopus
  165. J. Qin, J. Yao, G. Cui et al., “TLR8-mediated NF-κB and JNK activation are TAK1-independent and MEKK3-dependent,” Journal of Biological Chemistry, vol. 281, no. 30, pp. 21013–21021, 2006. View at Publisher · View at Google Scholar · View at Scopus
  166. L. Arbibe, J.-P. Mira, N. Teusch et al., “Toll-like receptor 2-mediated NF-κB activation requires a Rac1-dependent pathway,” Nature Immunology, vol. 1, no. 6, pp. 533–540, 2000. View at Publisher · View at Google Scholar · View at Scopus
  167. T. Ha, L. Liu, J. Kelley, R. Kao, D. Williams, and C. Li, “Toll-like receptors: new players in myocardial ischemia/reperfusion injury,” Antioxidants and Redox Signaling, vol. 15, no. 7, pp. 1875–1893, 2011. View at Publisher · View at Google Scholar · View at Scopus
  168. Q. Huang, J. Yang, Y. Lin et al., “Differential regulation of interleukin 1 receptor and toll-like receptor signaling by MEKK3,” Nature Immunology, vol. 5, no. 1, pp. 98–103, 2003. View at Publisher · View at Google Scholar · View at Scopus
  169. J. Wang, Y. Cai, L.-J. Shao et al., “Ctivation of NF-κB by TMPRSS2/ERG fusion isoforms through toll-like receptor-4,” Cancer Research, vol. 71, no. 4, 2011. View at Publisher · View at Google Scholar · View at Scopus
  170. J.-X. Wang, J.-Q. Jiao, Q. Li et al., “miR-499 regulates mitochondrial dynamics by targeting calcineurin and dynamin-related protein-1,” Nature Medicine, vol. 17, no. 1, pp. 71–78, 2011. View at Publisher · View at Google Scholar · View at Scopus
  171. A. V. Ougolkov, N. D. Bone, M. E. Fernandez-Zapico, N. E. Kay, and D. D. Billadeau, “Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor κB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells,” Blood, vol. 110, no. 2, pp. 735–742, 2007. View at Publisher · View at Google Scholar · View at Scopus
  172. A. V. Ougolkov, M. E. Fernandez-Zapico, D. N. Savoy, R. A. Urrutia, and D. D. Billadeau, “Glycogen synthase kinase-3β participates in nuclear factor κB-mediated gene transcription and cell survival in pancreatic cancer cells,” Cancer Research, vol. 65, no. 6, pp. 2076–2081, 2005. View at Publisher · View at Google Scholar · View at Scopus
  173. A. Shakoori, A. Ougolkov, Z. W. Yua et al., “Deregulated GSK3β activity in colorectal cancer: its association with tumor cell survival and proliferation,” Biochemical and Biophysical Research Communications, vol. 334, no. 4, pp. 1365–1373, 2005. View at Publisher · View at Google Scholar · View at Scopus
  174. J. S. Bae, M. K. Jang, S. Hong et al., “Phosphorylation of NF-κB by calmodulin-dependent kinase IV activates anti-apoptotic gene expression,” Biochemical and Biophysical Research Communications, vol. 305, no. 4, pp. 1094–1098, 2003. View at Publisher · View at Google Scholar · View at Scopus
  175. R. F. Schwabe and D. A. Brenner, “Role of glycogen synthase kinase-3 in TNF-α-induced NF-κB activation and apoptosis in hepatocytes,” American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 283, no. 1, pp. G204–G211, 2002. View at Publisher · View at Google Scholar · View at Scopus
  176. S. Sciarretta, N. Hariharan, Y. Monden, D. Zablocki, and J. Sadoshima, “Is autophagy in response to ischemia and reperfusion protective or detrimental for the heart?” Pediatric Cardiology, vol. 32, no. 3, pp. 275–281, 2011. View at Publisher · View at Google Scholar · View at Scopus
  177. J. Caamaño and C. A. Hunter, “NF-κB family of transcription factors: central regulators of innate and adaptive immune functions,” Clinical Microbiology Reviews, vol. 15, no. 3, pp. 414–429, 2002. View at Publisher · View at Google Scholar · View at Scopus
  178. A. Katsman, K. Umezawa, and B. Bonavida, “Chemosensitization and immunosensitization of resistant cancer cells to apoptosis and inhibition of metastasis by the specific NF-κB inhibitor DHMEQ,” Current Pharmaceutical Design, vol. 15, no. 7, pp. 792–808, 2009. View at Publisher · View at Google Scholar · View at Scopus
  179. K. D. Taganov, M. P. Boldin, K.-J. Chang, and D. Baltimore, “NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 33, pp. 12481–12486, 2006. View at Publisher · View at Google Scholar · View at Scopus
  180. L. Tornatore, A. K. Thotakura, J. Bennett, M. Moretti, and G. Franzoso, “The nuclear factor kappa B signaling pathway: integrating metabolism with inflammation,” Trends in Cell Biology, vol. 22, no. 11, pp. 557–566, 2012. View at Publisher · View at Google Scholar · View at Scopus
  181. N. H. Dryden, A. Sperone, S. Martin-Almedina et al., “The transcription factor Erg controls endothelial cell quiescence by repressing activity of nuclear factor (NF)-κB p65,” Journal of Biological Chemistry, vol. 287, no. 15, pp. 12331–12342, 2012. View at Publisher · View at Google Scholar · View at Scopus
  182. L. Li and M. D. Okusa, “Macrophages, dendritic cells, and kidney ischemia-reperfusion injury,” Seminars in Nephrology, vol. 30, no. 3, pp. 268–277, 2010. View at Publisher · View at Google Scholar · View at Scopus
  183. C. Duehrkop, Y. Banz, R. Spirig et al., “C1 esterase inhibitor reduces lower extremity ischemia/reperfusion injury and associated lung damage,” PLoS ONE, vol. 8, no. 8, Article ID e72059, 2013. View at Publisher · View at Google Scholar · View at Scopus
  184. M. R. G. A. Santos, A. C. Celotto, V. K. Capellini, P. R. B. Evora, C. E. Piccinato, and E. E. Joviliano, “The protective effect of cilostazol on isolated rabbit femoral arteries under conditions of ischemia and reperfusion: the role of the nitric oxide pathway,” Clinics, vol. 67, no. 2, pp. 171–178, 2012. View at Publisher · View at Google Scholar · View at Scopus
  185. Q. C. Yong, S. W. Lee, C. S. Foo, K. L. Neo, X. Chen, and J.-S. Bian, “Endogenous hydrogen sulphide mediates the cardioprotection induced by ischemic postconditioning,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 295, no. 3, pp. H1330–H1340, 2008. View at Publisher · View at Google Scholar · View at Scopus
  186. S. A. Gabel, V. R. Walker, R. E. London, C. Steenbergen, K. S. Korach, and E. Murphy, “Estrogen receptor beta mediates gender differences in ischemia/reperfusion injury,” Journal of Molecular and Cellular Cardiology, vol. 38, no. 2, pp. 289–297, 2005. View at Publisher · View at Google Scholar · View at Scopus
  187. E. Murphy and C. Steenbergen, “Gender-based differences in mechanisms of protection in myocardial ischemia-reperfusion injury,” Cardiovascular Research, vol. 75, no. 3, pp. 478–486, 2007. View at Publisher · View at Google Scholar · View at Scopus
  188. S. Renolleau, S. Fau, and C. Charriaut-Marlangue, “Gender-related differences in apoptotic pathways after neonatal cerebral ischemia,” The Neuroscientist, vol. 14, no. 1, pp. 46–52, 2008. View at Publisher · View at Google Scholar · View at Scopus
  189. D. A. Brown, J. M. Lynch, C. J. Armstrong et al., “Susceptibility of the heart to ischaemia-reperfusion injury and exercise-induced cardioprotection are sex-dependent in the rat,” Journal of Physiology, vol. 564, no. 2, pp. 619–630, 2005. View at Publisher · View at Google Scholar · View at Scopus
  190. P. S. Herson, J. Palmateer, and P. D. Hurn, “Biological sex and mechanisms of ischemic brain injury,” Translational Stroke Research, vol. 4, no. 4, pp. 413–419, 2013. View at Publisher · View at Google Scholar · View at Scopus
  191. A. Kher, K. K. Meldrum, M. Wang, B. M. Tsai, J. M. Pitcher, and D. R. Meldrum, “Cellular and molecular mechanisms of sex differences in renal ischemia-reperfusion injury,” Cardiovascular Research, vol. 67, no. 4, pp. 594–603, 2005. View at Publisher · View at Google Scholar · View at Scopus
  192. S. Cianchetti, A. Del Fiorentino, R. Colognato, R. Di Stefano, F. Franzoni, and R. Pedrinelli, “Anti-inflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells,” Atherosclerosis, vol. 198, no. 1, pp. 22–28, 2008. View at Publisher · View at Google Scholar · View at Scopus
  193. K. Hao, Y.-C. Chen, Y.-G. Cao, D. Yu, X.-Q. Liu, and G.-J. Wang, “Pharmacokinetic-pharmacodynamic modeling of telmisartan using an indirect response model in spontaneously hypertensive rats,” Acta Pharmacologica Sinica, vol. 28, no. 5, pp. 738–743, 2007. View at Publisher · View at Google Scholar · View at Scopus
  194. I. Imayama, T. Ichiki, K. Inanaga et al., “Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor γ,” Cardiovascular Research, vol. 72, no. 1, pp. 184–190, 2006. View at Publisher · View at Google Scholar · View at Scopus
  195. W. Z. Wang, “Investigation of reperfusion injury and ischemic preconditioning in microsurgery,” Microsurgery, vol. 29, no. 1, pp. 72–79, 2009. View at Publisher · View at Google Scholar · View at Scopus
  196. C. Dezfulian, M. Garrett, and N. R. Gonzalez, “Clinical application of preconditioning and postconditioning to achieve neuroprotection,” Translational Stroke Research, vol. 4, no. 1, pp. 19–24, 2013. View at Publisher · View at Google Scholar · View at Scopus
  197. P. Ferdinandy, R. Schulz, and G. F. Baxter, “Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning,” Pharmacological Reviews, vol. 59, no. 4, pp. 418–458, 2007. View at Publisher · View at Google Scholar · View at Scopus
  198. N. Gassanov, A. M. Nia, E. Caglayan, and F. Er, “Remote ischemic preconditioning and renoprotection: from myth to a novel therapeutic option?” Journal of the American Society of Nephrology, vol. 25, no. 2, pp. 216–224, 2014. View at Publisher · View at Google Scholar · View at Scopus
  199. A. Granfeldt, D. J. Lefer, and J. Vinten-Johansen, “Protective ischaemia in patients: preconditioning and postconditioning,” Cardiovascular Research, vol. 83, no. 2, pp. 234–246, 2009. View at Publisher · View at Google Scholar · View at Scopus
  200. D. J. Hausenloy and D. M. Yellon, “Remote ischaemic preconditioning: underlying mechanisms and clinical application,” Cardiovascular Research, vol. 79, no. 3, pp. 377–386, 2008. View at Publisher · View at Google Scholar · View at Scopus
  201. R. K. Kharbanda, T. T. Nielsen, and A. N. Redington, “Translation of remote ischaemic preconditioning into clinical practice,” The Lancet, vol. 374, no. 9700, pp. 1557–1565, 2009. View at Publisher · View at Google Scholar · View at Scopus
  202. S. P. Loukogeorgakis, A. T. Panagiotidou, D. M. Yellon, J. E. Deanfield, and R. J. MacAllister, “Postconditioning protects against endothelial ischemia-reperfusion injury in the human forearm,” Circulation, vol. 113, no. 7, pp. 1015–1019, 2006. View at Publisher · View at Google Scholar · View at Scopus
  203. J.-Y. Hahn, Y. B. Song, E. K. Kim et al., “Ischemic postconditioning during primary percutaneous coronary intervention: the POST Randomized Trial,” Circulation, vol. 134, no. 21, 2013. View at Publisher · View at Google Scholar
  204. D. Brevoord, P. Kranke, M. Kuijpers, N. Weber, M. Hollmann, and B. Preckel, “Remote ischemic conditioning to protect against ischemia-reperfusion injury: a systematic review and meta-analysis,” PLoS ONE, vol. 7, no. 7, Article ID e42179, 2012. View at Publisher · View at Google Scholar · View at Scopus